RxDoctor Payments Data

Samuel Davidoff, MD

Gastroenterology · Forest Hills, NYNPI 1922055276

Payments from drug & device makers

$301,335in general payments, 2019–2025

Across 1,419 payments — averaging $212.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$143K
  • AbbVie$98K
  • Eli Lilly$15K
  • Redhill Biopharma Inc.$10K
  • Ironwood Pharmaceuticals, Inc$9K
  • Madrigal Pharmaceuticals$5K
  • plus $21K from 38 others
$910in research payments, 2019–2025

Across 1 payment — averaging $910.39 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$910

What the payments were for

  • Consulting fees$14,3905%
  • Speaking & faculty fees$212,17574%
  • Travel & lodging$23,0888%
  • Food & beverage$36,32213%
  • Education$590%
  • Gifts$3000%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$301,335 in reported general payments places this provider in the 95th percentile of 1,682 gastroenterology providers in New York.

See all gastroenterology providers in New York

Medicare billing

Part B allowed, 2024
$264,121
Medicare patients
613
Services billed
5,916

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide921$500,874
StelaraUstekinumab12$360,869
ZenpepLipase/Protease/Amylase174$336,783
CreonLipase/Protease/Amylase261$304,547
XifaxanRifaximin88$214,143
IbsrelaTenapanor Hcl115$192,162
EntyvioVedolizumab15$149,022
OcalivaObeticholic Acid13$124,321
DexilantDexlansoprazole363$109,784
ViberziEluxadoline46$69,642
TrulancePlecanatide132$69,569
VemlidyTenofovir Alafenamide49$69,428
Lactulose20$54,306
Dexlansoprazole DrDexlansoprazole226$38,753
MotegrityPrucalopride Succinate68$36,231

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess, Creon, Viberzi$98,142$875,0621,228 claims
Johnson & JohnsonStelara$1,218$360,86912 claims
Aimmune Therapeutics, Inc.Zenpep$653$336,783174 claims
Takeda Pharmaceuticals U.S.A., Inc.Entyvio, Dexilant, Motegrity$2,253$295,037446 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance, Apriso$4,019$290,206233 claims
Ardelyx, Inc.Ibsrela$1,550$192,162115 claims
Intercept Pharmaceuticals, Inc.Ocaliva$757$124,32113 claims
GileadVemlidy$142,960$69,42849 claims
AstraZenecaNexium$19$33,473119 claims
E.r. Squibb & Sons, L.L.C.Baraclude$776$26,75321 claims
Ironwood Pharmaceuticals, IncCanasa$9,382$20,21819 claims
Phathom Pharmaceuticals, Inc.Voquezna$559$19,49730 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,682 gastroenterology providers in New York.

Other gastroenterology in Forest Hills

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →